HanchorBio Inc., a global biotechnology company dedicated to developing innovative immuno-medicines to address significant unmet medical needs in oncology and autoimmune diseases, has been awarded the 2025 Taiwan Biopharma Excellence Award at Biologics World Taiwan, hosted by IMAPAC. The company was also named “Company to Watch Out for in Taiwan”, recognizing its innovation, leadership, and growth potential in biologics development.
This industry recognition highlights HanchorBio’s significant progress in advancing its proprietary Fc-Based Designer Biologics (FBDB™) platform and underlines the company’s potential as it prepares for its next phase of corporate growth, including an anticipated IPO in Taiwan.
HanchorBio’s CEO, Dr. Scott Liu, and Senior Director of CMC (Chemistry, Manufacturing, and Controls), Dr. Vivian Kuo, were invited to the IMAPAC awards ceremony to receive this honor.
“This award is a testament to our team’s dedication to building a globally competitive biotech company in Taiwan,” said Scott Liu, Ph.D., Founder, Chairman, and CEO of HanchorBio. “We remain focused on expanding clinical development and providing better treatment options for patients worldwide while fostering talent and contributing to Taiwan’s biotech industry.”
Driving Innovation in Immunotherapy
HanchorBio’s proprietary FBDB™ platform leverages the antibody Fc region as a structural backbone to engineer next-generation multifunctional biologics with enhanced tumor specificity, improved safety, and durable efficacy. The platform integrates multi-target mechanisms to orchestrate both innate and adaptive immune responses, aiming to overcome the limitations of existing PD-1/PD-L1 checkpoint immunotherapies.
The company has successfully achieved proof-of-concept (PoC) for the FBDB™ platform in multiple tumor models, supported by strong progress in molecular design, manufacturing processes, and CMC (Chemistry, Manufacturing, and Controls) development.
Taiwan’s Emerging Global Biopharma Hub
The IMAPAC’s Taiwan Biopharma Excellence Awards recognize companies and teams driving innovation and operational excellence in biologics, cell therapies, and vaccine development. HachorBio’s award reflects its commitment to accelerating biopharma innovation and contributing to Taiwan’s growing influence in the global biotechnology ecosystem.
HanchorBio’s innovation in biologics R&D and high-quality manufacturing has earned industry-wide recognition for accelerating production timelines, reducing costs, and improving quality.
Advancing Clinical Development & Global Market Reach
HanchorBio’s lead candidate, HCB101, is currently being evaluated in multiple clinical trials across solid tumors and hematologic cancers:
• Phase 1a: Advanced solid tumors or relapsed/refractory non-Hodgkin lymphomas (NCT05892718)
• Phase 1b/2a: Evaluating efficacy and safety in advanced solid tumors
• Combination trials: HCB101 with cetuximab or bevacizumab + chemotherapy (FOLFOX or FOLFIRI) in RAS/BRAF wild-type metastatic colorectal cancer (NCT06771522)
HCB101 is a potential best-in-class Fc-fusion SIRPα variant designed to enhance immune activation with reduced hematologic toxicity. Compared to conventional CD47 monoclonal antibodies, HCB101 exhibits higher tumor-specific binding and significantly lower risk of anemia and thrombocytopenia, addressing a key limitation of existing macrophage checkpoint inhibitors.
Committed to Global Biotech Leadership
Winning the Taiwan Biopharma Excellence Award validates HanchorBio’s accomplishments and underscores its immense future potential. The recognition from IMPAC further validates HanchorBio’s innovative technology platform and its long-term strategy to become a leading global biotech company.
Dr. Scott Liu added, “We are committed to contributing to Taiwan’s biotech industry by building a globally competitive company. We aim to create an environment that attracts talent and provides more opportunities for young professionals in Taiwan.”
As global demand for cancer immunotherapies continues to rise, HanchorBio remains committed to advancing its pipeline and pursuing global partnerships to deliver accessible, next-generation immunotherapies for patients worldwide.